SCHEMBL4258060

SCHEMBL4258060

CCCCOC(=O)/C=C(/Oc1cccc([N+](=O)[O-])c1)C(=O)OCCCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
ALDH1A1 P00352 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
F2 P00734 1/20 0.43
HTT P42858 2/20 0.43
MAPT P10636 2/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNA4 P43681 1/20 0.42
LMNA P02545 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CACNA1F O60840 1/20 0.42
CACNA1D Q01668 1/20 0.42
CACNA1S Q13698 1/20 0.42
CACNA1C Q13936 1/20 0.42
HGFAC Q04756 1/20 0.42
ALOX5 P09917 1/20 0.42
GLO1 Q04760 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4250575 1.00 CYP3A4 (0.48) CYP3A4CYP2C9ALDH1A1TDP1MEN1
SCHEMBL4250580 1.00 CYP3A4 (0.48) CYP3A4CYP2C9ALDH1A1TDP1MEN1
SCHEMBL4251687 0.96 CACNA1F (0.47) CYP3A4CYP2C9TDP1MEN1KMT2A
SCHEMBL4250593 0.96 CACNA1F (0.47) CYP3A4CYP2C9TDP1MEN1KMT2A
SCHEMBL4250600 0.96 CACNA1F (0.47) CYP3A4CYP2C9TDP1MEN1KMT2A
SCHEMBL4256038 0.93 CYP3A4 (0.47) CYP3A4CYP2C9ALDH1A1MEN1KMT2A
SCHEMBL4250385 0.93 CYP3A4 (0.47) CYP3A4CYP2C9ALDH1A1MEN1KMT2A
SCHEMBL4250377 0.93 CYP3A4 (0.47) CYP3A4CYP2C9ALDH1A1MEN1KMT2A
SCHEMBL4252354 0.87 MGLL (0.53) CYP3A4CYP2C9ALDH1A1TDP1MEN1
SCHEMBL4256738 0.87 MGLL (0.53) CYP3A4CYP2C9ALDH1A1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2105432-A1 Process for Producing Chromone Compound Sumitomo Chemical Company, Limited (JP) 2009-09-30 EP disclosed
EP-2105431-A1 Process for Producing Chromone Compound Sumitomo Chemical Company, Limited (JP) 2009-09-30 EP disclosed
EP-1867626-A2 Process for producing chromone compound Sumitomo Chemical Company, Limited (JP) 2007-12-19 EP disclosed
US-20060217565-A1 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-28 US disclosed
US-7094914-B2 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-08-22 US disclosed
US-20050085664-A1 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LMITED (JP) 2005-04-21 US disclosed
EP-1479667-A1 PROCESS FOR PRODUCING CHROMONE COMPOUND Sumitomo Chemical Company, Limited (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085664-A1 Process for producing chromone compound ENY2, CDY1; CDY1B, CDYL CYP3A4 36/4885CYP2C9 61/4885ALDH1A1 3157/4885
US-20060217565-A1 Process for producing chromone compound ENY2, CDY1; CDY1B, CDYL CYP3A4 36/4885CYP2C9 61/4885ALDH1A1 3157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.